BMC Medicine | |
CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma | |
Research Article | |
Yong Li1  Lijuan Han2  Jianxiang Zhang2  Zhaoming Li3  Mingzhi Zhang3  Hongwen Li3  Jiwei Li3  Jiazhuo Wu4  Yuyang Gao4  Wenting Song4  Zhuangzhuang Shi4  | |
[1] Department of Medicine, Baylor College of Medicine, Houston, TX, USA;Department of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, 450052, Zhengzhou, Henan Province, China;Department of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, 450052, Zhengzhou, Henan Province, China;State Key Laboratory of Esophageal Cancer Prevention and Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Department of Oncology, Jianshendong Rd., The First Affiliated Hospital of Zhengzhou University, No. 1, 450052, Zhengzhou, Henan Province, China;State Key Laboratory of Esophageal Cancer Prevention and Treatment and Henan Key Laboratory for Esophageal Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China;Academy of Medical Sciences of Zhengzhou University, Zhengzhou, Henan, China; | |
关键词: CD38; LMP1; CAR-T; Tandem; Immunotherapy; NKTCL; | |
DOI : 10.1186/s12916-023-03040-0 | |
received in 2023-04-14, accepted in 2023-08-18, 发布年份 2023 | |
来源: Springer | |
【 摘 要 】
BackgroundNatural killer/T cell lymphoma (NKTCL) is an aggressive lymphoma with a poor prognosis. Chimeric antigen receptor-transduced T (CAR-T) cell therapy has become a promising immunotherapeutic strategy against haematologic malignancies.MethodsIn this study, four CAR-T cell lines (CD38-CAR, LMP1-CAR, CD38-LMP1 tandem CAR 1 and CD38-LMP1 tandem CAR 2) were generated. The effect of CAR-T cells against NKTCL cells was evaluated both in vitro and in vivo. Expression of T cell activation markers and cytokines produced by CAR-T cells were detected by flow cytometry.ResultsThe four CAR-T cell lines could effectively eliminate malignant NKTCL cells. They could be activated and produce inflammatory cytokines in a target-dependent manner. In vivo tests showed that the CAR-T cells exhibited significant antitumour effects in a xenotransplanted NKTCL mouse model.ConclusionsIn summary, four CAR-T cell lines exhibited significant cytotoxicity against NKTCL cells both in vitro and in vivo. These results indicated the effective therapeutic promise of CD38 and LMP1 CAR-T cells in NKTCL.
【 授权许可】
CC BY
© BioMed Central Ltd., part of Springer Nature 2023
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202309158906781ZK.pdf | 3330KB | download | |
MediaObjects/12944_2023_1886_MOESM5_ESM.txt | 1KB | Other | download |
MediaObjects/13046_2023_2774_MOESM4_ESM.docx | 18KB | Other | download |
Fig. 4 | 539KB | Image | download |
41512_2023_153_Article_IEq65.gif | 1KB | Image | download |
Fig. 6 | 368KB | Image | download |
【 图 表 】
Fig. 6
41512_2023_153_Article_IEq65.gif
Fig. 4
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]